跳到正文
原文
Endpoints News 生物医药· Elizabeth Cairns·· 11 天前AI 评分35

Boehringer 将申请 survo­du­tide 用于肥胖症的批准

#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky

AI 导读

Boehringer In­gel­heim 计划明年为 incretin 注射药 survo­du­tide 申请肥胖症适应症的批准。试验结果显示该药不会增加患者肥胖风险。

正文

Boehringer In­gel­heim will seek ap­proval for its in­cretin shot sur­vo­du­tide for obe­si­ty next year, af­ter a tri­al showed that the drug doesn’t in­crease pa­tients’ risk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news